priors.science/reviews/adhd-pharmacotherapy

Adhd Pharmacotherapy

The current evidence on 6 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

6claims tracked
54primary papers reviewed
5 Jun 2026latest evidence review
Weeklyre-scored against new papers
0 Established · 5 Likely · 1 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableViloxazine and guanfacine as approved non-stimulant alternatives for ADHDNon StimulantLikely82%10
StableAtomoxetine effective non-stimulant option for attention-deficit/hyperactivity disorderNon StimulantLikely80%9
StableStimulants cause minor cardiovascular changes with rare serious eventsSafety MonitoringLikely78%10
StableStimulants most effective pharmacotherapy for attention-deficit/hyperactivity disorderStimulant EfficacyLikely78%9
StableStimulants reduce attention-deficit/hyperactivity disorder symptoms in adultsStimulant EfficacyLikely69%6
StableLong-term stimulant use does not reliably prevent functional impairments in ADHDLong Term OutcomesUncertain61%10
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic